Tag: aGvHD
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program – 04/15/2024 at 07:40
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program:• Positive…